MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319912 | Name: Enviroxime
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Enviroxime, also known as LY 122772 and NSC 346230, is an anti-Infective and antiviral agent. Enviroxime targets the 3A coding region of rhinovirus and poliovirus. Combining enviroxime with disoxaril resulted in synergistic interaction.

Chemical Structure

Enviroxime
Enviroxime
CAS#72301-79-2

Theoretical Analysis

MedKoo Cat#: 319912

Name: Enviroxime

CAS#: 72301-79-2

Chemical Formula: C17H18N4O3S

Exact Mass: 358.1100

Molecular Weight: 358.42

Elemental Analysis: C, 56.97; H, 5.06; N, 15.63; O, 13.39; S, 8.94

Price and Availability

Size Price Availability Quantity
5mg USD 385.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
LY-122772; LY122772; LY 122772; LY122771-72; NSC 346230; NSC346230; NSC-346230; Enviroxime; Viroxime component B; Enviroxima; Viroxime; Enviroximum
IUPAC/Chemical Name
(E)-2-Amino-6-benzoyl-1-(isopropylsulfonyl)benzimidazole oxime
InChi Key
IWKXBHQELWQLHF-CAPFRKAQSA-N
InChi Code
InChI=1S/C17H18N4O3S/c1-11(2)25(23,24)21-15-10-13(8-9-14(15)19-17(21)18)16(20-22)12-6-4-3-5-7-12/h3-11,22H,1-2H3,(H2,18,19)/b20-16+
SMILES Code
O=S(N1C2=CC(/C(C3=CC=CC=C3)=N/O)=CC=C2N=C1N)(C(C)C)=O
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 358.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Levandowski RA, Pachucki CT, Rubenis M, Jackson GG. Topical enviroxime against rhinovirus infection. Antimicrob Agents Chemother. 1982 Dec;22(6):1004-7. doi: 10.1128/AAC.22.6.1004. PMID: 6297380; PMCID: PMC185710. 2: Brown-Augsburger P, Vance LM, Malcolm SK, Hsiung H, Smith DP, Heinz BA. Evidence that enviroxime targets multiple components of the rhinovirus 14 replication complex. Arch Virol. 1999;144(8):1569-85. doi: 10.1007/s007050050611. PMID: 10486111. 3: Delang L, Harak C, Benkheil M, Khan H, Leyssen P, Andrews M, Lohmann V, Neyts J. PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases. J Antimicrob Chemother. 2018 Dec 1;73(12):3375-3384. doi: 10.1093/jac/dky327. PMID: 30219827. 4: Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. J Virol. 2013 Apr;87(8):4252-60. doi: 10.1128/JVI.03546-12. Epub 2013 Jan 30. PMID: 23365445; PMCID: PMC3624399. 5: Heinz BA, Vance LM. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol. 1995 Jul;69(7):4189-97. doi: 10.1128/JVI.69.7.4189-4197.1995. PMID: 7769678; PMCID: PMC189156. 6: Wyde PR, Six HR, Wilson SZ, Gilbert BE, Knight V. Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes. Antimicrob Agents Chemother. 1988 Jun;32(6):890-5. doi: 10.1128/AAC.32.6.890. PMID: 2843086; PMCID: PMC172302. 7: Phillpotts RJ, Wallace J, Tyrrell DA, Tagart VB. Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob Agents Chemother. 1983 May;23(5):671-5. doi: 10.1128/AAC.23.5.671. PMID: 6870216; PMCID: PMC184785. 8: Hayden FG, Gwaltney JM Jr. Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrob Agents Chemother. 1982 Jun;21(6):892-7. doi: 10.1128/AAC.21.6.892. PMID: 6287928; PMCID: PMC182041. 9: Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J Virol. 2011 Mar;85(5):2364-72. doi: 10.1128/JVI.02249-10. Epub 2010 Dec 22. PMID: 21177810; PMCID: PMC3067798. 10: Phillpotts RJ, Jones RW, Delong DC, Reed SE, Wallace J, Tyrrell DA. The activity of enviroxime against rhinovirus infection in man. Lancet. 1981 Jun 20;1(8234):1342-4. doi: 10.1016/s0140-6736(81)92520-4. PMID: 6113314. 11: Miller FD, Monto AS, DeLong DC, Exelby A, Bryan ER, Srivastava S. Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrob Agents Chemother. 1985 Jan;27(1):102-6. doi: 10.1128/AAC.27.1.102. PMID: 2984980; PMCID: PMC176213. 12: Phillpotts RJ, Tyrrell DA. Rhinovirus colds. Br Med Bull. 1985 Oct;41(4):386-90. doi: 10.1093/oxfordjournals.bmb.a072081. PMID: 2996687. 13: Nikolaeva L, Galabov AS. Synergistic inhibitory effect of enviroxime and disoxaril on poliovirus type 1 replication. Acta Virol. 1995 Dec;39(5-6):235-41. PMID: 8722291. 14: Victor F, Brown TJ, Campanale K, Heinz BA, Shipley LA, Su KS, Tang J, Vance LM, Spitzer WA. Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime. J Med Chem. 1997 May 9;40(10):1511-8. doi: 10.1021/jm960718i. PMID: 9154972. 15: Higgins PG, Barrow GI, al-Nakib W, Tyrrell DA, DeLong DC, Lenox-Smith I. Failure to demonstrate synergy between interferon-alpha and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers. Antiviral Res. 1988 Nov;10(1-3):141-9. doi: 10.1016/0166-3542(88)90022-8. PMID: 3232968. 16: Gilbert BE, Six HR, Wilson SZ, Wyde PR, Knight V. Small particle aerosols of enviroxime-containing liposomes. Antiviral Res. 1988 Sep;9(6):355-65. doi: 10.1016/0166-3542(88)90037-x. PMID: 3228281. 17: Nikolaeva L, Galabov AS. Antiviral effect of the combination of enviroxime and disoxaril on coxsackievirus B1 infection. Acta Virol. 2000 Apr;44(2):73-8. PMID: 10989697. 18: Heinz BA, Vance LM. Sequence determinants of 3A-mediated resistance to enviroxime in rhinoviruses and enteroviruses. J Virol. 1996 Jul;70(7):4854-7. doi: 10.1128/JVI.70.7.4854-4857.1996. PMID: 8676522; PMCID: PMC190432. 19: Ninomiya Y, Aoyama M, Umeda I, Suhara Y, Ishitsuka H. Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RMI-15,731, 4',6-dichloroflavan, and enviroxime. Antimicrob Agents Chemother. 1985 Apr;27(4):595-9. doi: 10.1128/AAC.27.4.595. PMID: 2988431; PMCID: PMC180102. 20: Arita M. [Exploration for anti-enterovirus compounds and analysis on the mechanism of its inhibitory effect on virus infection]. Uirusu. 2013;63(1):93-102. Japanese. doi: 10.2222/jsv.63.93. PMID: 24769585.